Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ocuphire Pharma, Inc. OCUP
$6.08
-$0.26 (-4.25%)
На 18:04, 12 мая 2023
Ранг: 1
Ключевые показатели
-
Marketcap
120995540.00000000
-
week52high
6.50
-
week52low
1.78
-
Revenue
39850000
-
P/E TTM
20
-
Beta
-0.03340900
-
EPS
0.94000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 24 ноя 2021 г. | |
| Alliance Global Partners | Buy | 05 апр 2021 г. | |
| JonesTrading | Buy | 29 мар 2021 г. | |
| Cantor Fitzgerald | Overweight | Overweight | 15 мар 2021 г. |
| Canaccord Genuity | Buy | 10 февр 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rodgers Richard J | A | 88246 | 20822 | 11 янв 2023 г. |
| Pepose Jay | A | 45907 | 13013 | 11 янв 2023 г. |
| MANUSO JAMES S J | A | 55009 | 18544 | 11 янв 2023 г. |
| Benton Susan | A | 67433 | 16267 | 11 янв 2023 г. |
| Sooch Mina | A | 201683 | 201683 | 10 янв 2023 г. |
| Sooch Mina | A | 430501 | 134456 | 10 янв 2023 г. |
| Hoffmann Bernhard | A | 69912 | 69912 | 10 янв 2023 г. |
| Hoffmann Bernhard | A | 146728 | 46608 | 10 янв 2023 г. |
| Pepose Jay | A | 33291 | 33291 | 10 янв 2023 г. |
| Zaremba Rabourn Amy | A | 69912 | 69912 | 10 янв 2023 г. |
Новостная лента
What Makes Ocuphire Pharma, Inc. (OCUP) a Strong Momentum Stock: Buy Now?
Zacks Investment Research
06 февр 2023 г. в 13:33
Does Ocuphire Pharma, Inc. (OCUP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why Is Ocuphire Pharma (OCUP) Stock Down 20% Today?
InvestorPlace
26 янв 2023 г. в 09:25
Ocuphire Pharma (NASDAQ: OCUP ) stock is falling on Thursday after the company posted results from a Phase 2 clinical trial. The clinical trial evaluated the use of APX3330 as a treatment for diabetic retinopathy (DR).
Ocuphire to Present at Five Upcoming Investor/Industry Conferences
GlobeNewsWire
21 ноя 2022 г. в 08:00
FARMINGTON HILLS, Mich., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced that Mina Sooch, MBA, founder and CEO will present at several investor conferences in November and December, including the BTIG Ophthalmology Day, Alliance Global Partners (AGP) Biotech Conference, Ophthalmology Innovation Summit (OIS XII), Cantor Dermatology, Ophthalmology & Medtech Conference, and the Planet MicroCap Conference, being held on the following dates:
All You Need to Know About Ocuphire Pharma, Inc. (OCUP) Rating Upgrade to Buy
Zacks Investment Research
27 окт 2022 г. в 13:32
Ocuphire Pharma, Inc. (OCUP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Ocuphire Pharma to Present at the MicroCap Rodeo Windy City Roundup 2022 Conference
GlobeNewsWire
07 окт 2022 г. в 07:00
Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT Ocuphire to Present on Wednesday, October 12th @ 2:30 PM CT